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 Bugs  Battle  on  Behalf  of  the Liver
o  Tubo  Digestivo  Trava-se  uma  Batalha  pelo  Fígado
ariana Verdelho Machadoastroenterology  and  Hepatology  Department,  Hospital  de  Santa  Maria,  Centro  Hospitalar  de  Lisboa  Norte,  Lisbon,  Portugal
a
a
m
o
p
m
m
t
b
l
p
m
n
o
c
e
g
s
f
d
o
m
p
u
a
aonalcoholic  fatty  liver  disease  (NAFLD),  the  ectopic  accu-
ulation  of  fat  in  the  liver,  is  the  hepatic  manifestation
f  the  Western  lifestyle-associated  adiposopathy.  Excessive
aloric  intake  and  defective  energy  expenditure  overwhelm
he  adipose  tissue,  that  becomes  sick.  The  sick  adipose  tis-
ue  has  impaired  endocrine  function  releasing  potentially
asty  adipokines  (such  as  leptin  and  TNF-) in  detrimen-
al  of  health  promoting  ones  such  as  adiponectin.  It  also
annot  store  fat  appropriately,  allowing  fat  to  metastasize
nto  distant  organs  such  as  the  liver.  A  third  element  in
he  equation,  intestinal  microbiota,  deﬁnes  a  potent  axis,
ut-adipose  tissue-liver,  in  the  pathogenesis  of  NAFLD.
Our  gut  houses  ten  to  hundred  trillion  microbes,  at  least
0  times  more  the  number  of  cells  in  our  body.1 These  are
ot  unwanted  guests;  they  are  lifelong  residents  that  have
 crucial  role  in  maintaining  whole-body  homeostasis.  Also,
ur  gut  microbiota  is  speciﬁc  for  each  individual  and  is  highly
esilient,  easily  returning  to  the  basal  state  after  perturba-
ion.  Even  though  the  microbiota  is  speciﬁc,  because  there
s  a  huge  overlap  of  metabolic  functions  and  gene  expres-
ion  between  different  microorganisms,  humans  share  a
ore  functional  microbiome.2 Several  factors  can  modulate
he  gut  microbiota:  host-related  factors  such  as  genetics
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nd  antibiotics;  and  microbiota-related  factors,  because
icrobes  competitively  or  cooperatively  interact  with  each
ther.3 When  gut  microbiota  is  biased  to  a  disease-promoting
henotype,  called  dysbiota,  it  can  promote  the  develop-
ent  and  progression  of  NAFLD.  Several  studies  in  animal
odels  and  human  patients  with  NAFLD/NASH  tried  to  iden-
ify  a NAFLD-speciﬁc  dysbiota.4 However,  this  could  not  yet
een  deﬁned.  Those  studies  were  small,  often  without  histo-
ogical  diagnosis,  and  with  different  populations  precluding
ooled  evaluation.
Studies  with  animal  models  of  NAFLD/NASH  thought  us
ajor  concepts  regarding  the  gut-adipose  tissue-liver  axis:
ot  only  the  gut  dysbiota  has  a  crucial  role  in  the  devel-
pment  and  progression  of  NAFLD  and  NAFLD-associated
arcinogenesis,5 but  also,  NASH  can  be  a  transmissible  dis-
ase  through  the  sharing  of  the  gut  microbiota.6,7 The
ut  microbiota/dysbiota  can  promote  NAFLD/NASH  through
everal  mechanisms.  It  can  increase  the  energy  harvested
rom  diet  through  fermentation  of  indigestible  carbohy-
rates  into  different  short-chain  fatty  acids,  and  promote
besity  through  modulation  of  adipose  tissue  and  liver
etabolism.  Furthermore,  dysbiota  may  increase  intestinal
ermeability  and  endotoxemia,  it  can  produce  toxic  prod-
cts  such  as  ethanol,  impair  choline  metabolism  and  bile
cids  homeostasis.4
Although  NAFLD  is  an  extremely  frequent  condition,
nd  growing  to  expectedly  become  the  ﬁrst  cause  of  end-
8tage  liver  disease  in  the  Western  world, we  still  lack
n  effective  treatment.  As  such,  enthusiasm  and  expecta-
ions  in  targeting  the  gut  microbiota  for  the  management  of
AFLD  are  high.  In  fact,  several  pilot  studies  and  two  small
 by Elsevier Espan˜a, S.L.U. This is an open access article under the
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randomized  controlled  studies  addressed  the  effect  of  pro-
biotics  in  the  treatment  of  NAFLD/NASH.9--16 Despite  that,
we  still  lack  solid  evidence  on  the  role  of  probiotics  in  the
management  of  NAFLD,  which  precludes  its  recommenda-
tion.  Most  studies  are  small,  short-term,  and  heterogeneous
in  terms  of  design,  population  studied,  probiotic/symbiotic
used  and  end-points.  Only  two  studies  evaluated  the  effect
on  liver  ﬁbrosis,  one  noninvasively  through  the  determi-
nation  of  hepatic  transient  elastography,15 and  the  other
one  with  liver  biopsy,12 both  with  divergent  results.  In  fact,
human  studies  have  huge  limitations  in  assessing  a  real
impact  of  an  intervention  in  the  prognosis  of  NAFLD/NASH.
First  of  all  it  is  a  very  slowly  progressing  disease,  which
precludes  the  evaluation  of  potent  endpoints  such  as  sur-
vival  or  progression  to  end-stage  liver  disease.  The  best
way  to  infer  an  impact  in  the  prognosis  is  to  evaluate  the
effect  on  liver  ﬁbrosis,  however  because  ﬁbrosis  progression
is  also  slow,  it  implies  interventions  of  at  least  1--2  years  and
invasive  evaluation  with  liver  biopsy,  which  may  be  unethi-
cal  in  an  otherwise  asymptomatic  subject.  In  this  scenario,
and  because  there  is  a  huge  diversity  of  available  probio-
tics  and  symbiotics  (i.e.  the  combination  of  probiotics  and
prebiotics),  animal  studies  seem  crucial  to  move  the  ﬁeld
forward.
In  this  issue  of  the  Portuguese  Journal  of  Gastroenter-
ology,  Cortez-Pinto  et  al.  presented  a  preclinical  study  on
the  effect  of  a  symbiotic  preparation  in  the  management
of  NASH.17 They  took  advantage  of  the  high  fat  choline  deﬁ-
cient  diet  mouse  model  of  NASH.  This  is  a  good  animal  model
not  only  because  it  induces  severe  NASH  with  important
ﬁbrosis,  but  also  because  it  does  mimic  human  pathophy-
siology,  since  human  NAFLD  tends  to  associate  with  high  fat
content  in  the  diet  and  the  average  consumption  of  choline
in  the  general  population  is  half  the  required  dose.18 The
authors  fed  mice  with  a  regular  chow  diet  and  compared
to  high  fat  choline  deﬁcient  diet  with  or  without  supple-
mentation  with  Synbiotic  2000® Forte.  Synbiotic  2000® Forte
is  a  mixture  of  four  probiotic  strains  (Pediococcus  pen-
tosaceus,  Lactococcus  rafﬁnolectis, Latobacillus  paracasei
subsp.  paracasei  and  Lactobacillus  plantarum) and  four  pre-
biotics  (-glucan,  inulin,  pectin  and  resistant  starch)  that
was  shown  to  decrease  intestinal  permeability  and  the  risk
of  infection  in  critically  ill  children.19
Regarding  the  effect  of  the  symbiotic  preparation  in  the
gut  microbiota  among  mice  fed  the  NASH-inducing  diet,
results  were  inconsistent,  since  most  bacteria  evaluated
showed  divergent  results  at  week  6  or  week  18  of  treatment.
The  only  consistent  effect  was  a  decrease  in  the  abundance
of  Bacteroides  in  mice  supplemented  with  the  symbiotic.
This  is  a  relevant  ﬁnding  since  in  patients  with  NAFLD,
NASH  associates  with  higher  abundance  of  Bacteroides.20
The  potential  NASH-inducing  effect  of  Bacteroides  could  be
explained  by  an  increase  in  toxic  bile  acid  deoxycholic  acid,
which  not  only  is  increased  in  NASH,  but  it  is  a  direct  toxic  to
hepatocytes.21,22 Also,  Bacteroides  produce  branched-chain
fatty  acids  from  aminoacids  fermentation,  which  have  dia-
betogenic  potential.23 Supplementation  with  symbiotic  also
induced  a  decrease  in  serum  lipopolysaccharide  (LPS)  and
Gram-negative  bacteria  abundance  in  the  stool,  but  only
after  long-term  treatment  (18  weeks).
Evaluating  the  effect  of  an  intervention  in  the  micro-
biota  is  a  difﬁcult  task,  because  there  is  high  variability  in
t
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icrobiota  composition  in  the  basal  state,  even  in  highly
eproducible  and  controlled  conditions  such  as  in  inbred
ice.  Microbiota,  in  this  study,  was  assessed  by  Fluores-
ence  in  situ  hybridization  with  fourteen  16S  rRNA-targeted
ligonucleotide  probes  for  representative  species,  genera
r  families  from  ﬁve  phyla:  Firmicutes,  Bacteroidetes,  Pro-
eobacteria,  Fusobacteria,  Actinobacteria.  This  is  a  biased
pproach  that  does  not  allow  fully  characterization  of
hanges  in  the  microbiome  induced  by  the  intervention.
The  most  important  ﬁnding  in  this  study  was  partial
revention  to  NASH-related  liver  ﬁbrosis  (assessed  through
irius  red  staining  and  immunohistochemistry  for  the  hepatic
tellate  cells  activation  marker  -smooth  muscle  actin),
n  mice  supplemented  with  symbiotic.  This  is  highly  rele-
ant  because  liver  ﬁbrosis  is  the  histological  feature  that
etter  dictates  the  hepatic  prognosis  in  NAFLD.24,25 Inter-
stingly  the  decrease  in  ﬁbrosis  was  not  accompanied  by  an
mprovement  in  liver  metabolism/steatosis  or  liver  injury,
epatocellular  ballooning  or  inﬂammation.  This  is  surpris-
ng,  since  ﬁbrosis  is  believed  to  be  the  consequence  of
n  impaired/excessive  response  to  liver  injury.26 However,
n  the  same  NASH  mouse  model,  medication  with  non-
bsorbable  antibiotics  also  reduced  LPS  serum  levels  and
epatic  ﬁbrosis,  with  no  effect  in  liver  injury.27 Furthermore,
n  a different  mouse  model  of  NASH,  methionine--choline
eﬁcient  diet,  supplementation  with  the  probiotic  VSL#3
artially  prevented  ﬁbrosis,  while  having  no  effect  in  inﬂam-
ation  or  steatosis.28 On  the  contrary,  studies  on  high  fat
iet  did  accomplish  decreased  steatosis  and  liver  inﬂam-
ation  with  probiotic  supplementation.29--31 The  difference
ay  be  explained  by  the  different  mechanisms  of  steatoge-
esis  in  those  models:  while  high  fat  diet  induces  steatosis
hrough  an  increased  uptake  of  circulating  fatty  acids  arising
rom  the  adipose  tissue,  choline  deﬁcient  diets  are  steato-
enic  through  a  decrease  in  the  outﬂow  of  lipids  by  inhibiting
ipoprotein  synthesis.32 The  lack  of  effect  on  inﬂammation
s  more  difﬁcult  to  explain,  but  probably  this  study  would
eed  more  sensitive  assays  to  unravel  an  effect.  Probio-
ics  have  shown  to  decrease  inﬂammation,  pro-inﬂammatory
ytokines  levels  and  function  as  well  as  a  switch  to  an  M2
nti-inﬂammatory  phenotype  in  Kupffer  cells.29,33,34
The  protection  from  hepatic  ﬁbrogenesis  conferred  by
he  symbiotic  mixture,  may  translate  a  decrease  in  LPS-
nduced  activation  of  hepatic  stellate  cells.  In  fact,  LPS
ignaling  in  hepatic  stellate  cells,  through  toll-like  receptor
TLR)-4,  sensitizes  them  to  ﬁbrogenic  effect  of  transforming
rowth  factor  (TGF)-, by  down-regulation  of  the  TGF-
seudoreceptor  Bambi.35 However,  the  protection  from  liver
brosis  occurred  previously  to  the  decrease  in  serum  LPS  lev-
ls,  which  suggests  LPS-independent  mechanisms  conferring
rotection  against  ﬁbrosis.
In  conclusion,  gut  dysbiosis  seems  to  have  a  crucial  role
n  the  pathogenesis  of  obesity,  metabolic  syndrome  and
AFLD/NASH.  Since  there  is  no  effective  available  treat-
ent  for  NAFLD/NASH,  targeting  the  gut  microbiota  is  an
nticipated  good  candidate  approach  for  the  management
f  this  disease.  Despite  the  high  hopes  in  this  approach  by
he  scientiﬁc  community,  lack  of  solid  evidence  precludes
he  implementation  of  probiotics  in  the  clinical  practice  to
reat  NAFLD  patients.  The  confusion  in  the  ﬁeld  is  extraordi-
ary;  there  are  many  different  formulations  with  different
robiotics  and/or  prebiotics.  There  are  little  clues  of  how
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328  
ong  should  treatment  be  applied,  though  the  high  resilience
f  our  gut  microbiota  suggests  that  we  might  need  life-long
nterventions.  Human  studies  are  difﬁcult  to  implement  in  a
lowly-progressive  disease  such  as  NAFLD,  and  it  becomes
ssential  to  have  strong  preclinical  studies  guiding  the
esign  of  future  randomized  controlled  studies  in  humans.
his  study  further  increases  the  knowledge  in  the  ﬁeld  and
ives  hepatologists  extra  hope  in  the  probiotics  approach  in
AFLD,  by  showing  a  decrease  in  liver  ﬁbrosis,  the  strongest
rediction  of  morbi-mortality  in  NAFLD.
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